Linda Neuman, M.D.
Linda Neuman, M.D., M.B.A. is the interim chief medical officer for Adverum Biotechnologies. She joined Adverum as vice president, clinical development in October 2017. Dr. Neuman has 25 years of experience across multiple programs in both the pharmaceutical and biotechnology industries as well as in clinical practice. Prior to joining Adverum, Dr. Neuman served as vice president, clinical development at Sunesis Pharmaceuticals, Inc. where she led the filing of an Investigational New Drug (IND) Application and initiated a Phase 1b/2 clinical study. Before Sunesis, she worked as a senior medical director at Puma Biotechnology, Inc., where she worked on the successful New Drug Application (NDA) for neratininb. Previously, Dr. Neuman was medical director in clinical development at Onyx Pharmaceuticals. Earlier in her career, Dr. Neuman held roles of increasing responsibility at Covidien Pharmaceuticals, Millennium Pharmaceuticals, Inc., and Schering-Plough. She began her career as an internist and practiced medicine for 10 years prior to joining industry. Dr. Neuman earned an M.D. from Southern Illinois University School of Medicine, a B.S. in Biology from Southern Illinois University, and an M.B.A from Indiana Wesleyan University.